| 1 |
Zecca C, Terrazzino S, Para D, Campagna G, Viana M, Schankin CJ, Gobbi C. Response to erenumab assessed by Headache Impact Test-6 is modulated by genetic factors and arterial hypertension: An explorative cohort study. Eur J Neurol 2023;30:1099-108. [PMID: 36627267 DOI: 10.1111/ene.15678] [Reference Citation Analysis]
|
| 2 |
Ruscheweyh R, Diener H. Anwendung monoklonaler Antikörper zur Migräneprophylaxe in der Praxis. InFo Neurologie 2023;25:30-39. [DOI: 10.1007/s15005-023-3201-3] [Reference Citation Analysis]
|
| 3 |
Chaplin S. SIGN updates its guideline on the management of migraine. Prescriber 2023;34:9-10. [DOI: 10.1002/psb.2048] [Reference Citation Analysis]
|
| 4 |
Tepper SJ, Rabany L, Cowan RP, Smith TR, Grosberg BM, Torphy BD, Harris D, Vizel M, Ironi A, Stark-Inbar A, Blumenfeld AM. Remote electrical neuromodulation for migraine prevention: A double-blind, randomized, placebo-controlled clinical trial. Headache 2023. [PMID: 36704988 DOI: 10.1111/head.14469] [Reference Citation Analysis]
|
| 5 |
Fila M, Chojnacki J, Sobczuk P, Chojnacki C, Blasiak J. Nutrition and Calcitonin Gene Related Peptide (CGRP) in Migraine. Nutrients 2023;15. [PMID: 36678160 DOI: 10.3390/nu15020289] [Reference Citation Analysis]
|
| 6 |
Goßrau G, Förderreuther S, Ruscheweyh R, Ruschil V, Sprenger T, Lewis D, Kamm K, Freilinger T, Neeb L, Malzacher V, Meier U, Gehring K, Kraya T, Dresler T, Schankin CJ, Gantenbein AR, Brössner G, Zebenholzer K, Diener HC, Gaul C, Jürgens TP. [Consensus statement of the migraine and headache societies (DMKG, ÖKSG, and SKG) on the duration of pharmacological migraine prophylaxis]. Schmerz 2023;37:5-16. [PMID: 36287263 DOI: 10.1007/s00482-022-00671-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 7 |
Tkachenko E, Elkanov R, Raevskaya A, Vyshlova I, Karpov S. Monoclonal antibodies to calcitonin gene-related peptide receptor for episodic migraine on the example of erenumab. Rus Jour of Pain 2023;21:73. [DOI: 10.17116/pain20232101173] [Reference Citation Analysis]
|
| 8 |
Spekker E, Körtési T, Vécsei L. TRP Channels: Recent Development in Translational Research and Potential Therapeutic Targets in Migraine. Int J Mol Sci 2022;24. [PMID: 36614146 DOI: 10.3390/ijms24010700] [Reference Citation Analysis]
|
| 9 |
Chang CL, Cai Z, Hsu SYT. Gel-forming antagonist provides a lasting effect on CGRP-induced vasodilation. Front Pharmacol 2022;13:1040951. [PMID: 36569288 DOI: 10.3389/fphar.2022.1040951] [Reference Citation Analysis]
|
| 10 |
Yu S, Kim BK, Wang H, Zhou J, Wan Q, Yu T, Lian Y, Arkuszewski M, Ecochard L, Wen S, Yin F, Li Z, Su W, Wang SJ. A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study. J Headache Pain 2022;23:146. [PMID: 36404301 DOI: 10.1186/s10194-022-01514-9] [Reference Citation Analysis]
|
| 11 |
Ehrlich M, Hentschke C, Sieder C, Maier-peuschel M, Reuter U. Erenumab versus topiramate: post hoc efficacy analysis from the HER-MES study. J Headache Pain 2022;23:141. [DOI: 10.1186/s10194-022-01511-y] [Reference Citation Analysis]
|
| 12 |
Barbanti P, Egeo G, Aurilia C, Altamura C, d'Onofrio F, Finocchi C, Albanese M, Aguggia M, Rao R, Zucco M, Frediani F, Filippi M, Messina R, Cevoli S, Carnevale A, Fiorentini G, Messina S, Bono F, Torelli P, Proietti S, Bonassi S, Vernieri F; Italian Migraine Registry study group. Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients. J Headache Pain 2022;23:138. [PMID: 36316648 DOI: 10.1186/s10194-022-01498-6] [Reference Citation Analysis]
|
| 13 |
Sueiro AC, Santos ÉMD, Tundisi LL, Fava ALM, Silvério LAL, Coco JC, Ataide JA, Paiva-santos AC, Mazzola PG. Transdermal delivery systems for migraine treatment: A gap to explore. Journal of Drug Delivery Science and Technology 2022;77:103919. [DOI: 10.1016/j.jddst.2022.103919] [Reference Citation Analysis]
|
| 14 |
Yang D, Jacobson A, Meerschaert KA, Sifakis JJ, Wu M, Chen X, Yang T, Zhou Y, Anekal PV, Rucker RA, Sharma D, Sontheimer-Phelps A, Wu GS, Deng L, Anderson MD, Choi S, Neel D, Lee N, Kasper DL, Jabri B, Huh JR, Johansson M, Thiagarajah JR, Riesenfeld SJ, Chiu IM. Nociceptor neurons direct goblet cells via a CGRP-RAMP1 axis to drive mucus production and gut barrier protection. Cell 2022;185:4190-4205.e25. [PMID: 36243004 DOI: 10.1016/j.cell.2022.09.024] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 15 |
Goßrau G, Förderreuther S, Ruscheweyh R, Ruschil V, Sprenger T, Lewis D, Kamm K, Freilinger T, Neeb L, Malzacher V, Meier U, Gehring K, Kraya T, Dresler T, Schankin CJ, Gantenbein AR, Brössner G, Zebenholzer K, Diener HC, Gaul C, Jürgens TP. [Consensus statement of the migraine and headache societies (DMKG, ÖKSG, and SKG) on the duration of pharmacological migraine prophylaxis]. Nervenarzt 2022;:1-11. [PMID: 36287216 DOI: 10.1007/s00115-022-01403-1] [Reference Citation Analysis]
|
| 16 |
Okobi OE, Boms MG, Ijeh JC, Eboigbe SE, Alex KB, Adejola AA, Udo UA, Athem D, Oboh D, Olamilehin E, Ozobokeme OE, Adegbosin A, Nwaeke L, Evbayekha EO. Migraine and Current Pharmacologic Management. Cureus 2022;14:e29833. [PMID: 36337819 DOI: 10.7759/cureus.29833] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 17 |
Greco R, Demartini C, Francavilla M, Zanaboni AM, Tassorelli C. Antagonism of CGRP Receptor: Central and Peripheral Mechanisms and Mediators in an Animal Model of Chronic Migraine. Cells 2022;11:3092. [PMID: 36231054 DOI: 10.3390/cells11193092] [Reference Citation Analysis]
|
| 18 |
Russo M, De Rosa MA, Calisi D, Consoli S, Evangelista G, Dono F, Santilli M, Granzotto A, Onofrj M, Sensi SL. Migraine Pharmacological Treatment and Cognitive Impairment: Risks and Benefits. IJMS 2022;23:11418. [DOI: 10.3390/ijms231911418] [Reference Citation Analysis]
|
| 19 |
Cady R, Lipton RB, Buse DC, Josiassen MK, Lindsten A, Ettrup A. Optimization of acute medication use following eptinezumab initiation during a migraine attack: post hoc analysis of the RELIEF study. J Headache Pain 2022;23:91. [PMID: 35902796 DOI: 10.1186/s10194-022-01463-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 20 |
Varnado OJ, Hoyt M, Ye W, Nicholson R. Patient characteristics and treatment utilization among patients with migraine initiating self-injectable calcitonin gene-related peptide monoclonal antibody and novel acute medication. Curr Med Res Opin 2022;:1-11. [PMID: 35762152 DOI: 10.1080/03007995.2022.2091333] [Reference Citation Analysis]
|
| 21 |
Fitzek M, Raffaelli B, Reuter U. Advances in pharmacotherapy for the prophylactic treatment of resistant and refractory migraine. Expert Opin Pharmacother 2022;:1-11. [PMID: 35698795 DOI: 10.1080/14656566.2022.2088281] [Reference Citation Analysis]
|
| 22 |
Silvestro M, Tessitore A, Orologio I, De Micco R, Tartaglione L, Trojsi F, Tedeschi G, Russo A. Galcanezumab effect on "whole pain burden" and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience. J Headache Pain 2022;23:69. [PMID: 35698070 DOI: 10.1186/s10194-022-01436-6] [Reference Citation Analysis]
|
| 23 |
Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R, Katsarava Z, MaassenVanDenBrink A, Martelletti P, Mitsikostas DD, Ornello R, Reuter U, Sanchez-Del-Rio M, Sinclair AJ, Terwindt G, Uluduz D, Versijpt J, Lampl C. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. J Headache Pain 2022;23:67. [PMID: 35690723 DOI: 10.1186/s10194-022-01431-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 24 |
Sevivas H, Fresco P. Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review. Eur J Med Res 2022;27:86. [PMID: 35659086 DOI: 10.1186/s40001-022-00716-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 25 |
Fila M, Sobczuk A, Pawlowska E, Blasiak J. Epigenetic Connection of the Calcitonin Gene-Related Peptide and Its Potential in Migraine. Int J Mol Sci 2022;23:6151. [PMID: 35682830 DOI: 10.3390/ijms23116151] [Reference Citation Analysis]
|
| 26 |
Krymchantowski A, Silva-Néto RP, Jevoux C, Krymchantowski AG. Brazilian descriptive study of 104 consecutive real-world migraine patients treated with monoclonal antibodies. Postgrad Med 2022. [PMID: 35584542 DOI: 10.1080/00325481.2022.2080381] [Reference Citation Analysis]
|
| 27 |
Ambat FDF, Bentivegna E, Martelletti P. Novel Migraine Therapies May Reduce Public and Personal Disadvantages for People with Migraine. BioDrugs 2022. [PMID: 35575969 DOI: 10.1007/s40259-022-00532-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 28 |
Wang YF, Wang SJ. CGRP Targeting Therapy for Chronic Migraine-Evidence from Clinical Trials and Real-world Studies. Curr Pain Headache Rep 2022. [PMID: 35567661 DOI: 10.1007/s11916-022-01056-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 29 |
Kubota GT. It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine. Arq Neuro-Psiquiatr 2022;80:218-226. [DOI: 10.1590/0004-282x-anp-2022-s112] [Reference Citation Analysis]
|
| 30 |
Raggi A, Leonardi M, Sacco S, Martelletti P. Migraine Outcome Should Not Be Used to Determine Diagnosis, Severity, and Therapy: Moving Towards a Multiparametric Definition of Chronicity. Pain Ther. [DOI: 10.1007/s40122-022-00375-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 31 |
Domitrz I, Cegielska J. Magnesium as an Important Factor in the Pathogenesis and Treatment of Migraine—From Theory to Practice. Nutrients 2022;14:1089. [DOI: 10.3390/nu14051089] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 32 |
Martelletti P, Bentivegna E. Insights into headache 2022. Expert Rev Neurother 2022;:1-3. [PMID: 35142247 DOI: 10.1080/14737175.2022.2038135] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 33 |
Fernández-Bravo-Rodrigo J, Pascual-Morena C, Flor-García A, Saz-Lara A, Sequí-Dominguez I, Álvarez-Bueno C, Barreda-Hernández D, Cavero-Redondo I. The Safety and Efficacy of Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies for the Preventive Treatment of Migraine: A Protocol for Multiple-Treatment Systematic Review and Meta-Analysis. Int J Environ Res Public Health 2022;19:1753. [PMID: 35162776 DOI: 10.3390/ijerph19031753] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 34 |
Giraldo JP, Zarifkar P. Migraine Headache. Reference Module in Biomedical Sciences 2022. [DOI: 10.1016/b978-0-12-818872-9.00149-7] [Reference Citation Analysis]
|
| 35 |
Fila M, Chojnacki C, Chojnacki J, Blasiak J. Nutrients to Improve Mitochondrial Function to Reduce Brain Energy Deficit and Oxidative Stress in Migraine. Nutrients 2021;13:4433. [PMID: 34959985 DOI: 10.3390/nu13124433] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
|
